Do incretins improve endothelial function?

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Oyama, Jun ichi ^a   Higashi, Yukihito ^b   Node, Koichi ^a  

^a SAGA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Diabetes mellitus type 2; DPP 4 inhibitor; Endothelial function; GLP 1; Incretin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INCRETIN;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CELL FUNCTION; CLINICAL FEATURE; CLINICAL STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; EX VIVO STUDY; HUMAN; IN VIVO STUDY; LIPID METABOLISM; MORTALITY; MULTICENTER STUDY (TOPIC); PROGNOSIS; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; RISK FACTORS;

EID: 84892875170     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-21     Document Type: Review

References (58)

1. Lerman A, Burnett JC. Intact and altered endothelium in regulation of vasomotion. Circulation 1992, 86:III-12-II-19.
2. Uehata A, Lieberman EH, Gerhard MD, Anderson TJ, Ganz P, Polak JF, Creager MA, Yeung AC. Noninvasive assessment of endothelium-dependent flow-mediated dilation of the brachial artery. Vasc Med 1997, 2:87-92.
3. Anderson TJ, Uehata A, Gerhard MD. Close relationship of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995, 26:1235-1241. 10.1016/0735-1097(95)00327-4, 7594037.
4. Celermajer D. Endothelial dysfunction: does it matter? Is it reversible?. J Am Coll Cardiol 1997, 30:325-333. 10.1016/S0735-1097(97)00189-7, 9247501.
5. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987, 84:3434-3438. 10.1073/pnas.84.10.3434, 304885, 3033647.
6. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350. 10.1161/CIRCULATIONAHA.107.739938, 18427132.
7. Gallwitz B. Review of sitagliptin phosphate: a novel treatment for type 2 diabetes. Vasc Health Risk Manag 2007, 3:203-210. 10.2147/vhrm.2007.3.2.203, 1994027, 17580730.
8. Liu H, Hu Y, Simpson RW, Dear AE. Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen activator inhibitor-1 expression. J Endocrinol 2008, 196:57-65. 10.1677/JOE-07-0387, 18180317.
9. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 2010, 391:1405-1408. 10.1016/j.bbrc.2009.12.075, 20026306.
10. Ding L, Zhang J. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin 2012, 33:75-81. 10.1038/aps.2011.149, 22120969.
11. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010, 30:1407-1414. 10.1161/ATVBAHA.110.206425, 20448207.
12. Wang D, Luo P, Wang Y, Li W, Wang C, Sun D, Zhang R, Su T, Ma X, Zeng C, Wang H, Ren J, Cao F. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes 2013, 62:1697-1708. 10.2337/db12-1025, 23364453.
13. Aronis KN, Chamberland JP, Mantzoros CS. GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. Metabolism 2013, 62:1279-1286. 10.1016/j.metabol.2013.04.010, 23684008.
14. Liu FQ, Zhang XL, Gong L, Wang XP, Wang J, Hou XG, Sun Y, Qin WD, Wei SJ, Zhang Y, Chen L, Zhang MX. Glucagon-like peptide 1 protects microvascular endothelial cells by inactivating the PARP-1/iNOS/NO pathway. Mol Cell Endocrinol 2011, 339:25-33. 10.1016/j.mce.2011.03.007, 21458523.
15. Xiao-Yun X, Zhao-Hui M, Ke C, Hong-Hui H, Yan-Hong X. Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation. Med Sci Monit 2011, 17:BR35-BR41. 3524715, 21278683.
16. Erdogdu O, Nathanson D, Sjöholm A, Nyström T, Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 2010, 325:26-35. 10.1016/j.mce.2010.04.022, 20452396.
17. Erdogdu O, Eriksson L, Xu H, Sjöholm A, Zhang Q, Nyström T. Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. J Mol Endocrinol 2013, 50:229-241. 10.1530/JME-12-0166, 23343509.
18. Schisano B, Harte AL, Lois K, Saravanan P, Al-Daghri N, Al-Attas O, Knudsen LB, McTernan PG, Ceriello A, Tripathi G. GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress. Regul Pept 2012, 174:46-52. 10.1016/j.regpep.2011.11.008, 22120833.
19. Gaspari T, Liu H, Welungoda I, Hu Y, Widdop RE, Knudsen LB, Simpson RW, Dear AE. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. Diab Vasc Dis Res 2011, 8:117-124. 10.1177/1479164111404257, 21562063.
20. Shiraki A, Oyama J, Komoda H, Asaka M, Komatsu A, Sakuma M, Kodama K, Sakamoto Y, Kotooka N, Hirase T, Node K. The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 2012, 221:375-382. 10.1016/j.atherosclerosis.2011.12.039, 22284365.
21. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells. Horm Metab Res 2011, 43:731-734.
22. Shah Z, Pineda C, Kampfrath T, Maiseyeu A, Ying Z, Racoma I, Deiuliis J, Xu X, Sun Q, Moffatt-Bruce S, Villamena F, Rajagopalan S. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul Pharmacol 2011, 55:2-9. 10.1016/j.vph.2011.03.001, 21397040.
23. Han L, Yu Y, Sun X, Wang B. Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK-eNOS pathways. Diabetes Res Clin Pract 2012, 97:453-460. 10.1016/j.diabres.2012.04.001, 22560150.
24. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59:1030-1037. 10.2337/db09-1694, 2844811, 20068138.
25. Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE-/- mouse model. Diab Vasc Dis Res 2013, 10:353-360. 10.1177/1479164113481817, 23673376.
26. Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, Xu G, Pu Y, Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 2012, 60:833-841. 10.1161/HYPERTENSIONAHA.112.195115, 22868389.
27. Nathanson D, Erdogdu O, Pernow J, Zhang Q, Nyström T. Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo. Regul Pept 2009, 157:8-13. 10.1016/j.regpep.2009.07.003, 19595708.
28. Sakamoto Y, Oyama J, Ikeda H, Kuroki S, Gondo S, Iwamoto T, Uchida Y, Kodama K, Hiwatashi A, Shimomura M, Taguchi I, Inoue T, Node K, S-DOG investigators Effects of sitagliptin beyond glycemic control: focus on quality of life. Cardiol Diabetol 2013, 12:35. S-DOG investigators.
29. Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol 2013, 10:73-84. 10.1038/nrcardio.2012.183, 23296071.
30. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004, 89:3055-3061. 10.1210/jc.2003-031403, 15181098.
31. Huang PL, Huang Z, Mashimo H, Block KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995, 377:239-242. 10.1038/377239a0, 7545787.
32. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A 1989, 86:3375-3378. 10.1073/pnas.86.9.3375, 287135, 2497467.
33. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013, 19:567-575. 10.1038/nm.3128, 23542788.
34. Vanderheyden M, Bartunek J, Goethals M, Verstreken S, Lambeir AM, De Meester I, Scharpé S. Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside. Clin Chem Lab Med 2009, 47:248-252.
35. Flock G, Baggio LL, Longuet C, Drucker DJ. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 2007, 56:3006-3013. 10.2337/db07-0697, 17717280.
36. Qin X, Shen H, Liu M, Yang Q, Zheng S, Sabo M, D'Alessio DA, Tso P. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 2005, 288:G943-G949. 10.1152/ajpgi.00303.2004, 15677555.
37. Tesauro M, Schinzari F, Adamo A, Rovella V, Martini F, Mores N, Barini A, Pitocco D, Ghirlanda G, Lauro D, Campia U, Cardillo C. Effects of GLP-1 on forearm vasodilator function and glucose disposal during hyperinsulinemia in the metabolic syndrome. Diabetes Care 2013, 36:683-689. 10.2337/dc12-0763, 23069838.
38. Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, Bank AJ, Katz H. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial. Cardiovasc Diabetol 2012, 11:64. 10.1186/1475-2840-11-64, 3434036, 22681705.
39. Hopkins ND, Cuthbertson DJ, Kemp GJ, Pugh C, Green DJ, Cable NT, Jones H. Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients. Diabetes Obes Metab 2013, 15:770-773. 10.1111/dom.12089, 23451821.
40. Ayaori M, Iwakami N, Uto-Kondo H, Sato H, Sasaki M, Komatsu T, Iizuka M, Takiguchi S, Yakushiji E, Nakaya K, Yogo M, Ogura M, Takase B, Murakami T, Ikewaki K. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc 2013, 2:e003277. 3603233, 23525426.
41. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007, 293:E1289-E1295. 10.1152/ajpendo.00373.2007, 17711996.
42. Kubota Y, Miyamoto M, Takagi G, Ikeda T, Kirinoki-Ichikawa S, Tanaka K, Mizuno K. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci 2012, 27:1364-1370. 10.3346/jkms.2012.27.11.1364, 3492672, 23166419.
43. Nyström T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahrén B, Sjöholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209-E1215. 10.1152/ajpendo.00237.2004, 15353407.
44. Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care 2010, 33:1028-1030. 10.2337/dc09-1961, 2858168, 20200309.
45. Noda Y, Miyoshi T, Oe H, Ohno Y, Nakamura K, Toh N, Kohno K, Morita H, Kusano K, Ito H. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary report. Cardiovasc Diabetol 2013, 12:8. 10.1186/1475-2840-12-8, 3557163, 23298374.
46. van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care 2011, 34:2072-2077. 10.2337/dc10-2421, 3161271, 21788633.
47. Ceriello A, Esposito K, Testa R, Bonfigli AR, Marra M, Giugliano D. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an " endothelial resistance" to glucagon-like peptide 1 in diabetes. Diabetes Care 2011, 34:697-702. 10.2337/dc10-1949, 3041210, 21273492.
48. Irace C, De Luca S, Shehaj E, Carallo C, Loprete A, Scavelli F, Gnasso A. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diab Vasc Dis Res 2013, 10:72-77. 10.1177/1479164112449562, 22732108.
49. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, EXAMINE Investigators Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013, 369:1327-1335. 10.1056/NEJMoa1305889, 23992602, EXAMINE Investigators.
50. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369:1317-1326. 10.1056/NEJMoa1307684, 23992601, SAVOR-TIMI 53 Steering Committee and Investigators.
51. Gokce N, Keaney JF, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002, 105:1567-1572. 10.1161/01.CIR.0000012543.55874.47, 11927524.
52. Gokce N, Keaney JF, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, Vita JA. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003, 41:1769-1775. 10.1016/S0735-1097(03)00333-4, 12767663.
53. Widlansky ME, Gokce N, Keaney JF, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003, 42:1149-1160. 10.1016/S0735-1097(03)00994-X, 14522472.
54. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R, International brachial artery reactivity task force Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the international brachial artery reactivity task force. J Am Coll Cardiol 2002, 39:257-265. International brachial artery reactivity task force.
55. Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, Parker B, Widlansky ME, Tschakovsky ME, Green DJ. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol 2011, 300:H2-H12. 10.1152/ajpheart.00471.2010, 3023245, 20952670.
56. Hausenloy DJ, Whittington HJ, Wynne AM, Begum SS, Theodorou L, Riksen N, Mocanu MM, Yellon DM. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovasc Diabetol 2013, 12:154. 10.1186/1475-2840-12-154, 3815626, 24148218.
57. Hu G, Zhang Y, Jiang H, Hu X. Exendin-4 attenuates myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein expression. Cardiol J 2013, 20:600-604. 10.5603/CJ.2013.0159, 24338536.
58. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700. 10.1136/bmj.b2700, 2714672, 19622552.